Project Grant R01AI186092
Award Date
7/22/24
Completion Date
6/30/29
Dollars Obligated
$737K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bryan, TX 77807, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,413,412.00 to the Texas Biomedical Research Institute to conduct research on mechanisms for efficient control of Mycobacterium tuberculosis (TB) in the lungs prior to granuloma formation. The research aims to develop novel vaccination strategies to contain the TB pandemic, as the currently licensed Bacille...
This $447,009 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) categorize AM sensing abilities and identify negative regulators of AM innate sensing using a...
This $2,817,044 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a comprehensive research program to investigate the complex host-pathogen interactions that influence tuberculosis (TB) infection outcomes. The program leverages novel mouse genetic resources and large panels of Mycobacterium tuberculosis (MTB) strains to study how the combinatorial complexity of host and bacterial diversity...
The federal Project Grant award R01AI179891, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the design and development of a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The $1,350,312 award aims to develop a novel fluorescent trehalose-based diagnostic test, termed TRE-DST, that can quickly and accurately detect drug resistance in Mycobacterium...
This $787,171 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel compounds to treat tuberculosis (TB). The primary awardee, The Washington University, is leading efforts to identify and optimize 1,2,4-triazole and pyrrolidine compounds that demonstrate potent anti-TB activity, including against drug-resistant strains. Key objectives include...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop pro-apoptotic (cell-killing) drugs as host-directed therapies for pulmonary tuberculosis (TB). The $774,881 award will fund a 5-year project to evaluate how these novel drug therapies, such as the BCL-2 inhibitor navitoclax, can shorten TB treatment duration, improve bacterial clearance, and...
This Project Grant award, valued at $772,420.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research aimed at understanding the early interactions between macrophages and T cells, and the role of the SLAMF1 receptor, in the immune response to Mycobacterium tuberculosis (MTB) infection. Key objectives include determining the cell-type specific functions of SLAMF1,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,941 to The Johns Hopkins University to develop and evaluate pro-apoptotic drugs as host-directed treatments for pulmonary tuberculosis (TB). The goal is to utilize novel pro-apoptotic host-directed therapies (HDTs) to shorten TB treatment regimens from the current 4-6 months to 2-3 months, while also preventing...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research focused on understanding the early interactions between immune cells, such as macrophages and neutrophils, in response to Mycobacterium tuberculosis (MTB) infection and how HIV infection may alter these dynamics to increase susceptibility to active tuberculosis (TB). The primary awardee, The...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify and characterize the secreted proteins of Mycobacterium tuberculosis and understand their role in tuberculosis (TB) pathogenesis and immunity. The $820,246 award to the Albert Einstein College of Medicine will utilize a novel ESX5 mutant strain of the TB bacterium to investigate the...